Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty
Status:
Completed
Trial end date:
2020-12-20
Target enrollment:
Participant gender:
Summary
Primary aim of the study is to determine whether a rho kinase inhibitor, Netarsudil, can
speed corneal clearance after DWEK. Secondary aim of the study is to investigate whether
patient factors, such as baseline age, pachymetry, or endothelial cell count influence
response to Netarsudil.